DepoCyt™ - Near-term revenue driver

• Treats lymphomatous and solid tumor meningitis - 60,000 cases p.a. in US
  • Only FDA approved treatment
  • Approx. $10,000 per treatment
  • 7 years market exclusivity

• Chiron - U.S. marketing partner
  • Estimated $50 million p.a. in three years
  • 50/50 income split with Chiron

Previous slide

Next slide

Back to first slide

View graphic version